Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
31 Aug 2021
Historique:
received: 15 07 2021
revised: 05 08 2021
accepted: 25 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

Histone methyltransferase DOT1L catalyzes mono-, di- and trimethylation of histone 3 at lysine residue 79 (H3K79) and hypermethylation of H3K79 has been linked to the development of acute leukemias characterized by the MLL (mixed-lineage leukemia) rearrangements (MLLr cells). The inhibition of H3K79 methylation inhibits MLLr cells proliferation, and an inhibitor specific for DOT1L, pinometostat, was in clinical trials (Phase Ib/II). However, the compound showed poor pharmacological properties. Thus, there is a need to find new potent inhibitors of DOT1L for the treatment of rearranged leukemias. Here we present the design, synthesis, and biological evaluation of a small molecule that inhibits in the nM level the enzymatic activity of hDOT1L, H3K79 methylation in MLLr cells with comparable potency to pinometostat, associated with improved metabolic stability and a characteristic cytostatic effect.

Identifiants

pubmed: 34500733
pii: molecules26175300
doi: 10.3390/molecules26175300
pmc: PMC8434109
pii:
doi:

Substances chimiques

Cytostatic Agents 0
Histones 0
DOT1L protein, human EC 2.1.1.-
Histone-Lysine N-Methyltransferase EC 2.1.1.43

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Région Ile de France
ID : ARDoC
Organisme : DIM OneHealth Investissement
ID : EpiK
Organisme : Comité de Paris de la Ligue contre la Cancer
ID : Epi-Med 2020-2021
Organisme : Program Pavle Savic 2020
ID : Hubert Curien Partnership Project
Organisme : European Cooperation in Science and Technology
ID : CM1406 Epigenetic Chemical Biology

Références

Nat Rev Cancer. 2007 Nov;7(11):823-33
pubmed: 17957188
Nat Rev Genet. 2012 Apr 03;13(5):343-57
pubmed: 22473383
Epigenetics. 2020 May;15(5):439-453
pubmed: 31790636
Epigenomics. 2020 Sep;12(17):1479-1482
pubmed: 32938211
Mol Cell. 2019 Jan 3;73(1):61-72.e3
pubmed: 30472189
Leukemia. 2004 Feb;18(2):227-32
pubmed: 14671638
Toxicol Mech Methods. 2011 May;21(4):252-74
pubmed: 21495865
Proteins. 2003 Sep 1;52(4):609-23
pubmed: 12910460
Blood. 2013 Aug 8;122(6):1017-25
pubmed: 23801631
ACS Med Chem Lett. 2016 Jun 06;7(8):730-4
pubmed: 27563394
Nat Commun. 2012;3:1288
pubmed: 23250418
Bioorg Med Chem. 2005 Feb 1;13(3):877-82
pubmed: 15653353
Biopharm Drug Dispos. 2014 May;35(4):237-52
pubmed: 24415392
ACS Med Chem Lett. 2017 Feb 14;8(3):338-343
pubmed: 28337327
Acta Biochim Biophys Sin (Shanghai). 2016 Jul;48(7):603-16
pubmed: 27217472
Blood Adv. 2018 Nov 27;2(22):3137-3148
pubmed: 30463913
Semin Cancer Biol. 2020 Aug 16;:
pubmed: 32814115
Cell. 2005 Apr 22;121(2):167-78
pubmed: 15851025
Cell Cycle. 2015;14(21):3345-6
pubmed: 26375309
Genes Dev. 2003 Sep 15;17(18):2298-307
pubmed: 12952893
Cancer Cell. 2011 Jul 12;20(1):66-78
pubmed: 21741597
Mol Cell Biol. 2004 Jan;24(2):617-28
pubmed: 14701735
Cancer Cell. 2011 Jul 12;20(1):53-65
pubmed: 21741596
Stem Cells. 2009 Jul;27(7):1538-47
pubmed: 19544450
Chembiochem. 2011 Jun 14;12(9):1337-45
pubmed: 21633996
Oncogenesis. 2014 Dec 22;3:e135
pubmed: 25531430
Sci Rep. 2020 Nov 26;10(1):20636
pubmed: 33244015
ACS Med Chem Lett. 2016 Jun 01;7(8):735-40
pubmed: 27563395
Genes Dev. 2011 Jul 1;25(13):1345-58
pubmed: 21724828
Curr Opin Genet Dev. 2002 Apr;12(2):198-209
pubmed: 11893494
Oncotarget. 2020 Mar 17;11(11):956-968
pubmed: 32215184
Biosci Rep. 2020 Jan 31;40(1):
pubmed: 31939604
Signal Transduct Target Ther. 2019 Dec 17;4:62
pubmed: 31871779
Front Pediatr. 2017 Feb 09;5:4
pubmed: 28232907
ACS Med Chem Lett. 2019 Dec 04;10(12):1655-1660
pubmed: 31857842
Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-49
pubmed: 16261189
Vaccines (Basel). 2020 Apr 01;8(2):
pubmed: 32244625

Auteurs

Corentin Bon (C)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.
Ecole Doctorale MTCI, Université de Paris, Sorbonne Paris Cité, 75006 Paris, France.

Yang Si (Y)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Melanie Pernak (M)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Magdalena Barbachowska (M)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.
Ecole Doctorale MTCI, Université de Paris, Sorbonne Paris Cité, 75006 Paris, France.

Eva Levi-Acobas (E)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Veronique Cadet Daniel (V)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Corinne Jallet (C)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Dusan Ruzic (D)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.

Nemanja Djokovic (N)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.

Teodora Djikić (T)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.

Katarina Nikolic (K)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.

Ludovic Halby (L)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Paola B Arimondo (PB)

Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR3523 CNRS, 75015 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH